New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
06:31 EDTVRX, JNJ, AGN, NSRGYValeant prepared to make higher offer for Allergan, says Wells Fargo
Wells Fargo said it left Valeant (VRX) and Pershing Square's sell-side meeting Friday with the impression that Valeant is prepared to go higher than the current offer for Allergan (AGN), which it notes is about $159 per share at closing prices on April 25. Wells pointed out that Valeant and Pershing indicated that Nestle (NSRGY) was the most likely potential additional bidder for Allergan followed by Johnson & Johnson (JNJ). Wells has an Outperform rating on Allergan.
News For AGN;VRX;NSRGY;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 4, 2015
07:35 EDTJNJNewYorkBio to hold a conference
Subscribe for More Information
May 3, 2015
18:11 EDTJNJSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
16:49 EDTJNJJ&J says Costco filed complaint against Vision Care unit
Subscribe for More Information
07:43 EDTJNJExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
07:43 EDTVRXValeant named a new Top Pick at Barclays
Barclay's Doug Taso raised Valeant's (VRX) price target to $275 from $230 and named its his Top Pick following the Q1 report and recent management meetings that increased his confidence that earnings growth can be higher than consensus expectations. Management inferred that the Marathon and Salix (SLXP) acquisitions will drive much higher gross margins and the analyst believes the deal pipeline remains strong and dealmaking should continue. The firm has an Overweight rating on Valeant shares.
06:47 EDTVRXValeant price target raised to $271 from $222 at Cantor
Cantor increased its price target on Valeant after the company reported stronger than expected Q1 results. The firm thinks the company's U.S. sales could approach $7.4B this year and surpass $10B in 2016. It keeps a Buy rating on the shares.
April 29, 2015
17:00 EDTJNJJohnson & Johnson announces further patent action related to Remicade
Subscribe for More Information
12:25 EDTJNJPerrigo rumored to possibly draw interest beyond Mylan bid, Bloomberg says
Subscribe for More Information
06:13 EDTVRXValeant announces CFO succession plan
Subscribe for More Information
06:12 EDTVRXValeant sees accretion from Salix acquisition over 20% in FY16
Subscribe for More Information
06:11 EDTVRXValeant raises FY15 cash EPS view to $10.90-$11.20 from $10.10-$10.40
Subscribe for More Information
06:11 EDTVRXValeant sees Q2 cash EPS $2.40-$2.50, consensus $2.45
Subscribe for More Information
06:07 EDTVRXValeant reports Q1 cash EPS $2.36, consensus $2.34
Subscribe for More Information
April 28, 2015
10:19 EDTVRXPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
07:43 EDTNSRGYMead Johnson pushing for changes to WIC program, WSJ reports
The law authorizing the $6B per year WIC program providing food vouchers to women who are pregnant or have young children is up for renewal this year and formula makers, led by top U.S. maker Mead Johnson (MJN), are pushing for change, said The Wall Street Journal. Growth in the program has made it a money-losing venture for baby formula makers who essentially make no profit off formula sold to states as part of the program and Mead Johnson is pushing for changing eligibility requirements, thereby limiting or even shrinking the pool of recipients, the report noted. Other U.S. infant formula makers include Abbott (ABT) and Nestle (NSRGY). Reference Link
April 27, 2015
06:19 EDTVRX, JNJPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.
April 23, 2015
14:20 EDTJNJEarnings Watch: Google up close to 8.5% since last earnings report
Subscribe for More Information
11:02 EDTJNJJohnson & Johnson increases dividend by 7.1% to 75c
Subscribe for More Information
10:02 EDTJNJAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use